Save on Sarclisa with Coupons, Discounts & Savings Programs

Sarclisa is the brand name for isatuximab-irfc and is available as an intravenous infusion.

Sarclisa is available as a 100 mg/5 mL (20 mg/mL) or 500 mg/25 mL (20 mg/mL) solution in single-dose vial.

Sarclisa is a monoclonal antibody that treats multiple myeloma in adults who’ve received previous therapies. It is typically given two other medications.

Sarclisa is an anti-CD38 monoclonal antibody that attaches to CD38 proteins on the surface of cancer cells. Once attachesd, it sends signals to the immune system to come attack it. Sometimes, the medication can attack the cell itself. This helps stop the cancer from growing and spreading.

The typical dose of Sarclisa is 10 mg/kg of body weight given once a week for the first cycle (4 weeks). For the following cycles, the medication is given once every 2 weeks. You will be premedicated with dexamethasone, acetaminophen, H2 antagonists, and diphenhydramine prior to your infusion.

Sarclisa is a safe and effective treatment when used for FDA licensed indications. However, like all medications, they may give you unwanted side effects. You should always discuss potential side effects with your physician to ensure the medication is suitable and right for you. You should not use this medication in the following:

• Severe hypersensitivity to isatuximab-irfc or to any of its excipients

Common side effects of Sarclisa:

• Lower red blood cell counts
• Lower white blood cell counts
• Lower platelet counts
• Upper respiratory infection
• Infusion-related reaction
• Tiredness
• High blood pressure
• Diarrhea
• Trouble breathing
• Cough

Serious side effects are rare with Sarclisa. Contact your healthcare provider immediately if you experience any of the following:

• Serious reaction during infusion: itching, cough, trouble breathing, fast heart beat, face swelling, feeling warm or hot
• Low white blood cells: fever, signs of infection (e.g., cough, body aches, chills)

There are no major drug interactions listed for this medication. However, always let your physician and pharmacist know about any other medications or supplements (including prescribed and over-the-counter medications, vitamins, and dietary or herbal supplements) that you are currently taking.

Sanofi-Aventis U.S.

Sarclisa can harm your unborn baby. Females who are able to become pregnant should use an effective method of birth control during treatment and for 5 months after your last dose. Tell your healthcare provider right away if you think you are pregnant or become pregnant during treatment.

• Isatuximab-Irfc